BioSpace News Archive

NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) announces a partnership with Eyeganics to sell OTC Organic Tears (0.2% organic glycerin) on Avenova.com and through Avenova’s physician-dispensed channel.

KronosMD, INC. announced today that it has successfully acquired all existing and future assets and intellectual property related to its upcoming innovative 3D ultrasound dental imaging and diagnostic devices.

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced that an abstract has been selected for an oral presentation at the 4th International Pancreas and Islet Transplant Association / Harvard Stem Cell Institute / Juvenile Diabetes Research Fund Summit, to be held from April 24-25, 2023 in Cambridge, Massachusetts.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2022.

TScan Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 1 umbrella trial of TSC-100 and TSC-101 targeting minor histocompatibility antigens (MiHA) HA-1 and HA-2.

Switch Therapeutics today announced its launch following $52 million of financing.

Servier announced today that the Phase 3 INDIGO clinical trial investigating vorasidenib in monotherapy for patients with residual or recurrent IDH mutant low-grade glioma met its primary endpoint of progression free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI).

InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – capped off another successful year in 2022.

Newron Pharmaceuticals S.p.A. today announced its financial results and operational highlights for the business year ended December 31, 2022, and provided an outlook for 2023.

Repligen Corporation today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22.